Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Using two instead of three or four drugs could potentially lead to cost savings in the billions.
Providing antiretroviral starter packs for selected patients who test HIV positive is feasible and safe.
The all-oral regimen maintained viral suppression in people with resistance to multiple antiretrovirals.
Doxycycline after sex reduces the risk of gonorrhea, chlamydia and syphilis for gay men, and it does not appear to drive resistance.
People with HIV who recently used marijuana were twice as likely to miss taking their meds.
Taking medications consistently is the best way to avoid resistance mutations.
Long-acting antiretrovirals are the future of HIV treatment, and new meds on the horizon could improve convenience and adherence.
The long-acting HIV capsid inhibitor worked well for harder-to-treat groups, such as those with a low CD4 count.
The long-acting monoclonal antibody, approved for people with highly resistant HIV, can now be administered in 30 seconds.
The injectable antiretroviral could potentially be given once every six months for HIV treatment or prevention.
Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.